SCHEMBL1966769

SCHEMBL1966769

COC(=O)c1nc(N(C)C)sc1-c1cccc(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.49
PKM P14618 2/20 0.49
HSD17B10 Q99714 6/20 0.48
ALDH1A1 P00352 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
HPGD P15428 5/20 0.48
USP2 O75604 1/20 0.46
MAPT P10636 2/20 0.45
LMNA P02545 2/20 0.44
RCE1 Q9Y256 1/20 0.44
NPC1 O15118 3/20 0.43
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
RAB9A P51151 3/20 0.43
HTT P42858 1/20 0.43
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980763 0.89 PIN1 (0.51) KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL2056904 0.86 KDM4E (0.49) KDM4EPKMHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL2056772 0.85 KDM4E (0.48) KDM4EPKMHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL982254 0.84 KDM4E (0.52) KDM4EPKMHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL269345 0.84 KDM4E (0.52) KDM4EPKMHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL982083 0.82 KDM4E (0.72) KDM4EPKMHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL2056664 0.80 KDM4E (0.48) KDM4EPKMHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL7938350 0.79 FLT3 (0.47) KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL1141172 0.79 HCRTR1 (0.53) KDM4EPKMHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL2056898 0.77 KDM4E (0.50) KDM4EPKMHSD17B10ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed
EP-2334643-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES Actelion Pharmaceuticals Ltd. (CH) 2011-06-22 EP disclosed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US disclosed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 WO disclosed
WO-2010038200-A1 OXAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-04-08 WO disclosed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR KDM4E 3641/4885PKM 2689/4885HSD17B10 1862/4885
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 KDM4E 452/4885PKM 2251/4885HSD17B10 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.